Trinity Biotech (TRIB) Announces FDA Approval for for Destiny Max
More News related to TRIB
- Morning Movers 7/7: GY, SOMX, CHLN, HOKU, TRIB Higher; HNSN, AXL, DFS Lower
- Trinity Biotech (TRIB) Announces FDA Approval for for Destiny Max
- Morning Movers 6/12: SVNT, CRXX, APPY, RMBS, VICL Higher; HOKU, ARST, EZPW, OCLS, CPST Lower
- Unusual 11 Mid-Day Movers 4/29: DNDN, SRZ, WYN, SVVS Higher; ETFC, BCRX, VISN, NVAX Lower
- Trinity Biotech (TRIB) Receives CE Marking and Announces European Launch of Destiny Max
More News related to FDA
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
- Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb
- Dynavax Tech (DVAX) Initiates HEPLISAV Phase 3
Trinity Biotech plc (NASDAQ: TRIB) announced the FDA approval and US launch of its high throughput haemostasis analyzer, the Destiny Max.
Key features of the Destiny Max include:
- -- being the only high throughput instrument on the worldwide market that allows simultaneous and automated measurement of mechanical and optical clot detection, chromogenic and immuno-turbidimetric assays;
- -- best in class graphical user interface and touch screen technology;
- -- the most reliable and novel cap piercing solution on the market.
Related Categories
FDAStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
